2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013
DateTitle 
05/03/16Ionis Pharmaceuticals and Kastle Therapeutics Announce Acquisition of KYNAMRO®
CARLSBAD, Calif. and CHICAGO, May 3, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Kastle Therapeutics, LLC today announced that Kastle has acquired global rights to develop and commercialize KYNAMRO (mipomersen sodium) injection. KYNAMRO is approved in the United States for use in patients with homozygous familial hypercholesterolemia (HoFH) to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC) and non-high density lipoprote... 
Printer Friendly Version
04/22/16Webcast Alert: Ionis Pharmaceuticals' First Quarter 2016 Financial Results Conference Call
- Webcast scheduled for Wednesday, May 4 at 10:30 a.m. Eastern Time CARLSBAD, Calif., April 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 4 at 10:30 a.m. Eastern Time to discuss its first quarter 2016 financial results, and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A webcast replay will be ... 
Printer Friendly Version
04/20/16Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise
Webcast scheduled for Thursday, April 21 at 11:00 a.m. PDT/ 2:00 p.m. EDT CARLSBAD, Calif., April 20, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on its ongoing open-label Phase 2 clinical study of nusinersen in infants with spinal muscular atrophy (SMA) at the American Academy of Neurology (AAN) meeting in Vancouver, BC.  The data reported today show that there have been no new events, as defined by progression to permanent ventilation or death, i... 
Printer Friendly Version
04/15/16Ionis Pharmaceuticals Highlights Antisense Drugs to Treat Neurological Diseases at the AAN Meeting
Ionis and its collaborators to present more than 12 presentations and posters on Ionis' neurological disease programs Webcast to provide update on nusinersen Phase 2 open-label study in infants with SMA and to review Ionis' other neurological disease programs scheduled for Thursday, April 21 at 2:00 p.m. EDT CARLSBAD, Calif., April 15, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Ionis and its collaborators will present a dozen presentations and post... 
Printer Friendly Version
04/07/16Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program
CARLSBAD, Calif., April 7, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on the IONIS-TTRRx program. IONIS-TTRRx is currently being evaluated by IONIS in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy. A Phase 3 study, CARDIO-TTR, is also being planned by GSK to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy.  GSK is in the process of finalizing the protocol for the CARDI... 
Printer Friendly Version
04/06/16Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., April 6, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a company overview at the 15th Annual Needham Healthcare Conference at 4:40 p.m. ET on Tuesday, April 12, 2016 in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the I... 
Printer Friendly Version
04/01/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., April 1, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 in New York, NY; 41st Annual Deutsche Bank Health Care Conference on Thursday, May 5, 2016 in Boston, MA; and Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, ... 
Printer Friendly Version
03/31/16Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA
Ionis Earns $7.5M Milestone Payment from Biogen CARLSBAD, Calif., March 31, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a milestone payment of $7.5 million from Biogen for advancing nusinersen in the open-label extension study, SHINE. The SHINE study was initiated in October 2015 to provide nusinersen to infants and children with spinal muscular atrophy (SMA) who have completed their participation in the Phase 3 ENDEAR and CHERISH studies... 
Printer Friendly Version
03/31/16Akcea Therapeutics Supports World Lipodystrophy Day
CAMBRIDGE, Mass., March 31, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, recognizes World Lipodystrophy Day and has partnered with Lipodystrophy United (lipodystrophyunited.org) to raise awareness of those living with lipodystrophy. "We are proud to join forces with the patient community in celebration of World Lipodystrophy Day. We stand in support... 
Printer Friendly Version
03/22/16Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case
CARLSBAD, Calif., March 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a jury in the United States District Court, Northern District of California found in favor of Merck and Ionis in a patent dispute related to Gilead's sofosbuvir-based medicines for the treatment of hepatitis C virus (HCV), including Sovaldi and Harvoni.  The jury found in favor of Merck and Ionis upholding all claims from the two patents in the case, including two methods an... 
Printer Friendly Version
03/04/16Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
CAMBRIDGE, Mass., March 4, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a company overview at the Cowen and Company 36th Annual Health Care Conference at 2:30 p.m. ET on Tuesday, March 8, 2016 in Boston, MA. A live webcast of the presentation will be available on the "Investors & Media" section ... 
Printer Friendly Version
02/29/16Ionis Pharmaceuticals Supports Rare Disease Day
CARLSBAD, Calif., Feb. 29, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) recognizes International Rare Disease Day and has partnered with the Amyloidosis Research Consortium (arci.org), Cure SMA (curesma.org), and Myotonic Dystrophy Foundation (MDF.org) to raise awareness of those living with rare diseases. As part of Ionis' initiative to recognize the value of bringing together researchers, patients, caregivers and advocacy groups, Ionis will be hosting a seminar for its emplo... 
Printer Friendly Version
02/25/16Ionis' 2015 Financial Results Outperform Projections
- Ended 2015 with More Than $775M in Cash - Completed Target Enrollment in Three Phase 3 Studies for Nusinersen, IONIS-TTR(Rx) and Volanesorsen - Multiple Clinical Data Readouts Planned in 2016 from Large Pipeline of First-in-class or Best-in-class Drugs - Conference Call Webcast Thursday, February 25, 11:30 a.m. ET at www.ionispharm.com CARLSBAD, Calif., Feb. 25, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported it ended the year in a strong financial po... 
Printer Friendly Version
02/11/16Ionis Pharmaceuticals to Hold 2015 Financial Results Conference Call
- Webcast scheduled for Thursday, February 25 at 11:30 a.m. Eastern Time CARLSBAD, Calif., Feb.11, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Thursday, February 25 at 11:30 a.m. Eastern Time to discuss its 2015 financial results and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A webcast replay will be a... 
Printer Friendly Version
02/04/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 in New York, NY; Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 in Boston, MA; 28th Annual ROTH Conference on Monday, March 14, 2016 in Dana Point, CA; ... 
Printer Friendly Version
01/19/16Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Appointment adds depth in clinical and regulatory leadership CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced the appointment of Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C) as the company's Chief Medical Officer.  Dr. O'Dea will lead medical, clinical, and regulatory functions in support of volanesorsen and will al... 
Printer Friendly Version
01/13/16Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx
Ionis Earns $1.5M Milestone Payment CARLSBAD, Calif., Jan. 13, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that GSK has initiated a Phase 1 study of IONIS-HBV-LRx.  Ionis earned a $1.5 million milestone payment from GSK related to the initiation of this study.  IONIS-HBV-LRx, which was previously referred to as ISIS-GSK6-LRx, is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus (HBV).  IONIS-HBV-LRx incorporates Ionis'... 
Printer Friendly Version
01/12/16Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Ionis Earns $2.15M Milestone Payment from Biogen as Nusinersen Advances CARLSBAD, Calif., Jan. 12, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a milestone payment of $2.15 million from Biogen for completing the target enrollment of the Phase 3 CHERISH study. The study is designed to support marketing approval of nusinersen in children with spinal muscular atrophy (SMA).   "Achieving our target enrollment number in CHERISH brings us ... 
Printer Friendly Version
01/11/16Ionis Pharmaceuticals Revises 2015 Financial Guidance and Provides Pipeline Update in Conjunction with J.P. Morgan Conference
Significantly improved net operating loss and increased cash projected CARLSBAD, Calif., Jan. 11, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the Company expects to significantly improve upon its financial guidance for 2015.  The Company expects to end 2015 with a pro forma net operating loss (NOL) in the low $20 million range and more than $775 million in cash.  "Over the past several years, we have created a strong and consistent financial foun... 
Printer Friendly Version
01/05/16Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
First therapy designed to directly target the cause of disease CARLSBAD, Calif., Jan. 5, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD). IONIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein respon... 
Printer Friendly Version
01/04/16Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.ionispharma.com. A replay will be available on the Ioni... 
Printer Friendly Version